IL6 and systemic inflammatory response syndrome: These results demonstrated that the h‐mIL‐6R mAb was capable of blocking IL‐6/mIL‐6R signaling and inhibiting LPS‐induced inflammatory signaling activation, which was in consistent with our results of the LPS‐induced murine SIRS model.